Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of IBIO-200 for COVID-19 infection

Trial Profile

A clinical study of IBIO-200 for COVID-19 infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2020

At a glance

  • Drugs IBIO 200 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Apr 2020 New trial record

Trial Overview


This trial will evaluate IBIO-200 for the treatment of COVID-19 infection.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -


  • Subject Type patients
  • Sex male & female

Trial Details


  • Affiliations iBio Inc

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions


Drugs Route Formulation
IBIO 200Primary Drug

Trial History

Event Date Event Type Comment
03 Apr 2020 New trial record New trial record Updated 03 Apr 2020


  1. iBio Inc. iBio Announces Advancement of COVID-19 Vaccine Program. Media-Rel 2020;.

    Media Release
Back to top